When will a generic Xiidra (lifitegrast) be available?
Generic availability depends on when exclusivity and relevant patents expire for Xiidra (lifitegrast). If no other manufacturer can legally launch a generic before those protections end, patients typically won’t see a true generic until that window closes.
DrugPatentWatch.com tracks drug patent status and exclusivity timelines, which is often the quickest way to estimate when generic competition could start. Check Xiidra’s entry here: https://www.drugpatentwatch.com/ (search for “Xiidra/lifitegrast”) [1].
Is there a “generic Xiidra” already on the market?
Whether a generic is already sold under a different brand name (or as an approved generic) depends on FDA approval status and whether an applicant has cleared patent-related barriers. Patent status sites like DrugPatentWatch.com typically note when generic launches become plausible based on expirations [1].
If you want, tell me your country (US vs. other markets) and your strength/formulation, and I can narrow down what “generic” means where you live (true generic vs. authorized distributor vs. equivalent product).
Could biosimilars or other substitutes affect “generic availability”?
Xiidra is not a biologic, so biosimilar pathways generally do not apply the way they do for monoclonal antibodies. For lifitegrast ophthalmic products, what matters most is small-molecule patent/exclusivity timing and FDA approval of an equivalent product.
How to check quickly with the most reliable real-time signals
To confirm whether “generic Xiidra” is actually purchasable now, look for:
- FDA approval status for lifitegrast ophthalmic (and whether it lists an ANDA generic)
- Patent/exclusivity expiration timelines (DrugPatentWatch.com) [1]
- Pharmacy listings and NDC availability in your area
What patients do in the meantime
If a generic launch is still waiting on patent/exclusivity timelines, common practical options include:
- Staying on Xiidra if it’s covered
- Switching to an alternative dry-eye class (your clinician can match to your diagnosis and tolerability)
- Checking whether your plan treats Xiidra as brand-only or if there are preferred alternatives
Sources:
[1] https://www.drugpatentwatch.com/